Keros Therapeutics Inc. (KROS)
NASDAQ (NMS) NASDAQ (NMS) Primary 
Why Is Keros Therapeutics (KROS) Up 2.5% Since Last Earnings Report?
Keros Therapeutics (KROS) reported earnings 30 days ago. What's next for the stock?
KROS Stock: What to Know About Rinvatercept in DMD
Keros advances rinvatercept in DMD with orphan status, fresh phase I data, and a planned Q2 2026 phase II start driving its near-term execution story.
KROS: Is the Discount Book Value a Value Trap?
Keros posts a 2025 revenue surge from Takeda licensing, but no product sales and volatile drivers leave investors weighing a discounted valuation against execution risk.
KROS Pipeline Catalysts: DMD Phase II and ALS Plans for 2026
Keros lines up 2026 catalysts with rinvatercept at the core, including a Q2 DMD phase II start and ALS regulatory plans as execution shifts into focus.
Keros Therapeutics, Inc. (NASDAQ:KROS) Receives Average Recommendation of “Hold” from Analysts
Keros Therapeutics, Inc. (NASDAQ: KROS - Get Free Report) has been assigned a consensus recommendation of "Hold" from the ten analysts that are presently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and five have issued a buy recommendation on the company.
Can Keros Therapeutics Rinvatercept Stand Out in the DMD Market?
KROS advances rinvatercept for Duchenne muscular dystrophy, with a phase II trial planned for 2026 after gaining FDA orphan drug designation.
Keros Therapeutics, Inc. (KROS) Reports Q4 Loss, Misses Revenue Estimates
Keros Therapeutics, Inc. (KROS) came out with a quarterly loss of $0.86 per share versus the Zacks Consensus Estimate of a loss of $0.49. This compares to a loss of $1.14 per share a year ago.
Should Investors Buy, Sell or Hold KROS Stock Ahead of Q4 Earnings?
KROS investors eye pipeline updates as rinvatercept advances in DMD and Takeda-backed elritercept hits milestones ahead of Q4 results.
Keros Therapeutics vs. Dyne: Which DMD Biotech Has More Upside?
Keros Therapeutics KROS is a clinical-stage biopharmaceutical company developing innovative therapies for patients with disorders caused by abnormal signaling within the transforming growth factor-beta (TGF-β) protein family.
Is KROS' KER-065 the Next Breakthrough in DMD Space?
KROS is advancing KER-065 for Duchenne muscular dystrophy, with orphan drug status and a phase II trial planned for early 2026.
Will KROS Stock's Restructuring Efforts Reap Rewards for Investors?
Keros Therapeutics sharpens focus on KER-065 for DMD, cuts staff 45%, shelves cibotercept, and plans a phase II trial in Q1 2026 with cash runway into 2028.
KROS Stock Surges 85.6% in a Year: More Upside Potential in 2026?
KROS shares are up 85.6% in a year, driven by a strategic review and pipeline progress led by KER-065 and elritercept, which have fueled investor enthusiasm.
